Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049653 · ClinicalTrials.gov registry record
Anifrolumab Pregnancy Study
A clinical trial, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 500
- Enrollment target
NCT07049653: Recruiting study, sponsored by AstraZeneca.
NCT07049653 is a clinical trial that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07049653 is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
This is a non-interventional multi-database post-authorisation study to assess pregnancy-related safety data from women with SLE exposed to Anifrolumab.
Primary Outcome
Describe and estimate the risk of MCM in live and non-live offspring from the women who had moderate/severe SLE and were exposed to anifrolumab during the first trimester of pregnancy or exposed to SOC and unexposed to anifrolumab during the first trimester of pregnancy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-06-04 |
| Est. Completion | 2030-12-10 |
What NCT07049653 shows while recruiting
NCT07049653 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07049653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07049653 about?
NCT07049653 is a clinical study titled "Anifrolumab Pregnancy Study". This is a non-interventional multi-database post-authorisation study to assess pregnancy-related safety data from women with SLE exposed to Anifrolumab.
What is the current status of trial NCT07049653?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2026-06-04. Estimated completion is 2030-12-10.
Who is sponsoring clinical trial NCT07049653?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI